公开(公告)号：EP1325751A4

公开(公告)日：2005-05-04

申请号：EP01972593

申请日：2001-09-28

申请人： DAIICHI SEIYAKU CO ,  EGASHIRA KENSUKE

发明人： EGASHIRA KENSUKE ,  TAKESHITA AKIRA ,  KOYANAGI MASAMICHI ,  NAKAMUTA MAKOTO ,  NISHIDA KENICHI

IPC分类号： A61K38/19 ,  A61K48/00 ,  A61P1/16 ,  A61P43/00 ,  A61K45/00

CPC分类号： A61K38/195 ,  A61K48/00

摘要： Preventives and/or remedies for liver diseases containing as the active ingredient monocyte chemoattractant protein-1 (MCP-1) function inhibitors. Administration of the MCP-1 function inhibitors exerts effects of preventing and/or treating liver diseases.

公开(公告)号：EP1447095A4

公开(公告)日：2009-08-05

申请号：EP02779986

申请日：2002-11-01

申请人： EGASHIRA KENSUKE

发明人： EGASHIRA KENSUKE ,  TAKESHITA AKIRA ,  SATA MASATAKA

IPC分类号： A61K31/00 ,  A61K38/00 ,  A61P9/10 ,  A61P37/06 ,  C07K14/52 ,  A61K45/00 ,  A61K39/395 ,  A61K48/00

CPC分类号： C07K14/523 ,  A61K31/00 ,  A61K38/00

摘要： Preventives and/or remedies for post-transplant arteriosclerosis as a rejection of organ transplant or endosporium thickening after self-homogeneous arteriovenous graft transplant which contain a monocyte chemotactic protein-1 MCP-1 inhibitor as the active ingredient. Administration of the MCP-1 inhibitor makes it possible to prevent or treat post-transplant arteriosclerosis as a rejection of organ transplant and endosporium thickening after self-homogeneous arteriovenous graft transplant.